Cargando…

The Brief Negative Symptom Scale: external validation of symptom domains with clinical, cognitive and functioning-related variables in subjects with schizophrenia

INTRODUCTION: Negative symptoms (NS) represent a heterogeneous construct of schizophrenia, whose conceptualization is still to be clarified. In the last decade, the conceptualization model that has received the most support from the literature has described 2 NS domains: the expressive deficit (EXP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Giordano, G. M., Mucci, A., Rucci, P., Sanmarchi, F., Caporusso, E., Giuliani, L., Perrottelli, A., Pezzella, P., Bucci, P., Rocca, P., Rossi, A., Bertolino, A., Galderisi, S., Maj, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596358/
http://dx.doi.org/10.1192/j.eurpsy.2023.602
_version_ 1785125085487562752
author Giordano, G. M.
Mucci, A.
Rucci, P.
Sanmarchi, F.
Caporusso, E.
Giuliani, L.
Perrottelli, A.
Pezzella, P.
Bucci, P.
Rocca, P.
Rossi, A.
Bertolino, A.
Galderisi, S.
Maj, M.
author_facet Giordano, G. M.
Mucci, A.
Rucci, P.
Sanmarchi, F.
Caporusso, E.
Giuliani, L.
Perrottelli, A.
Pezzella, P.
Bucci, P.
Rocca, P.
Rossi, A.
Bertolino, A.
Galderisi, S.
Maj, M.
author_sort Giordano, G. M.
collection PubMed
description INTRODUCTION: Negative symptoms (NS) represent a heterogeneous construct of schizophrenia, whose conceptualization is still to be clarified. In the last decade, the conceptualization model that has received the most support from the literature has described 2 NS domains: the expressive deficit (EXP), which includes blunted affect and alogia, and the motivational deficit (MAP), which includes avolition, asociality, and anhedonia. However, different confirmatory factor-analytic studies suggest that the bi-dimensional model may not capture the complexity of this construct, which could be better defined by a 5-factor model (5 individual negative symptoms) or a hierarchical model (5 individual negative symptoms as first-order factors, and the 2 domains, MAP and EXP domains, as second-order factors). However, to our knowledge, no study has investigated associations between negative symptom models with social cognition and functional capacity, which are largely documented to correlate with negative symptoms, nor the associations with external validators over time, looking at the potential stability of negative symptom models validity through the course of the illness. OBJECTIVES: In the light of this observations, we investigated, the external validity of the five-factor model and the hierarchical model of the BNSS in subjects with schizophrenia, looking at associations with cognition, social cognition, functioning and functional capacity at baseline and at four years follow-up. METHODS: NS were assessed in 612 subjects with schizophrenia using the Brief Negative Symptom Scale at the baseline and after 4-year follow-up. State of the art assessment instruments were used to assess cognitive and functioning related variables. Structural equation models (SEM) that included the NS models and 4 external variables were used to our aim. RESULTS: According to recent multicenter studies, our results confirmed the validity of the 5-factor- and the hierarchical-model of negative symptoms. In particular, these 2 models proved to be equivalent in terms of fit to the data at baseline and follow-up. As regard to the relationship of the two BNSS models with external variables, we found that there was a similar pattern of associations at the two time points despite minor variations. CONCLUSIONS: The five factor and the hierarchical models provide an optimal conceptualization of negative symptoms in relation to external variables. The similar pattern of associations with external variables of the two models at the two time points despite minor variations, suggests that the simple and widely used 5-factor solution provides the best balance between parsimony and granularity to summarize BNSS structure. This data is of important relevance with consequent implications in the study of pathophysiological mechanisms and the development of targeted treatments for NS. DISCLOSURE OF INTEREST: None Declared
format Online
Article
Text
id pubmed-10596358
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-105963582023-10-25 The Brief Negative Symptom Scale: external validation of symptom domains with clinical, cognitive and functioning-related variables in subjects with schizophrenia Giordano, G. M. Mucci, A. Rucci, P. Sanmarchi, F. Caporusso, E. Giuliani, L. Perrottelli, A. Pezzella, P. Bucci, P. Rocca, P. Rossi, A. Bertolino, A. Galderisi, S. Maj, M. Eur Psychiatry Abstract INTRODUCTION: Negative symptoms (NS) represent a heterogeneous construct of schizophrenia, whose conceptualization is still to be clarified. In the last decade, the conceptualization model that has received the most support from the literature has described 2 NS domains: the expressive deficit (EXP), which includes blunted affect and alogia, and the motivational deficit (MAP), which includes avolition, asociality, and anhedonia. However, different confirmatory factor-analytic studies suggest that the bi-dimensional model may not capture the complexity of this construct, which could be better defined by a 5-factor model (5 individual negative symptoms) or a hierarchical model (5 individual negative symptoms as first-order factors, and the 2 domains, MAP and EXP domains, as second-order factors). However, to our knowledge, no study has investigated associations between negative symptom models with social cognition and functional capacity, which are largely documented to correlate with negative symptoms, nor the associations with external validators over time, looking at the potential stability of negative symptom models validity through the course of the illness. OBJECTIVES: In the light of this observations, we investigated, the external validity of the five-factor model and the hierarchical model of the BNSS in subjects with schizophrenia, looking at associations with cognition, social cognition, functioning and functional capacity at baseline and at four years follow-up. METHODS: NS were assessed in 612 subjects with schizophrenia using the Brief Negative Symptom Scale at the baseline and after 4-year follow-up. State of the art assessment instruments were used to assess cognitive and functioning related variables. Structural equation models (SEM) that included the NS models and 4 external variables were used to our aim. RESULTS: According to recent multicenter studies, our results confirmed the validity of the 5-factor- and the hierarchical-model of negative symptoms. In particular, these 2 models proved to be equivalent in terms of fit to the data at baseline and follow-up. As regard to the relationship of the two BNSS models with external variables, we found that there was a similar pattern of associations at the two time points despite minor variations. CONCLUSIONS: The five factor and the hierarchical models provide an optimal conceptualization of negative symptoms in relation to external variables. The similar pattern of associations with external variables of the two models at the two time points despite minor variations, suggests that the simple and widely used 5-factor solution provides the best balance between parsimony and granularity to summarize BNSS structure. This data is of important relevance with consequent implications in the study of pathophysiological mechanisms and the development of targeted treatments for NS. DISCLOSURE OF INTEREST: None Declared Cambridge University Press 2023-07-19 /pmc/articles/PMC10596358/ http://dx.doi.org/10.1192/j.eurpsy.2023.602 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Giordano, G. M.
Mucci, A.
Rucci, P.
Sanmarchi, F.
Caporusso, E.
Giuliani, L.
Perrottelli, A.
Pezzella, P.
Bucci, P.
Rocca, P.
Rossi, A.
Bertolino, A.
Galderisi, S.
Maj, M.
The Brief Negative Symptom Scale: external validation of symptom domains with clinical, cognitive and functioning-related variables in subjects with schizophrenia
title The Brief Negative Symptom Scale: external validation of symptom domains with clinical, cognitive and functioning-related variables in subjects with schizophrenia
title_full The Brief Negative Symptom Scale: external validation of symptom domains with clinical, cognitive and functioning-related variables in subjects with schizophrenia
title_fullStr The Brief Negative Symptom Scale: external validation of symptom domains with clinical, cognitive and functioning-related variables in subjects with schizophrenia
title_full_unstemmed The Brief Negative Symptom Scale: external validation of symptom domains with clinical, cognitive and functioning-related variables in subjects with schizophrenia
title_short The Brief Negative Symptom Scale: external validation of symptom domains with clinical, cognitive and functioning-related variables in subjects with schizophrenia
title_sort brief negative symptom scale: external validation of symptom domains with clinical, cognitive and functioning-related variables in subjects with schizophrenia
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596358/
http://dx.doi.org/10.1192/j.eurpsy.2023.602
work_keys_str_mv AT giordanogm thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT muccia thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT ruccip thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT sanmarchif thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT caporussoe thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT giulianil thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT perrottellia thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT pezzellap thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT buccip thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT roccap thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT rossia thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT bertolinoa thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT galderisis thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT majm thebriefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT giordanogm briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT muccia briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT ruccip briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT sanmarchif briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT caporussoe briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT giulianil briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT perrottellia briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT pezzellap briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT buccip briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT roccap briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT rossia briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT bertolinoa briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT galderisis briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia
AT majm briefnegativesymptomscaleexternalvalidationofsymptomdomainswithclinicalcognitiveandfunctioningrelatedvariablesinsubjectswithschizophrenia